Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical practice. Raynaud's Phenomenon.
Wigley FM. Wigley FM. N Engl J Med. 2002 Sep 26;347(13):1001-8. doi: 10.1056/NEJMcp013013. N Engl J Med. 2002. PMID: 12324557 Review. No abstract available.
Raynaud's Phenomenon.
Wigley FM, Flavahan NA. Wigley FM, et al. N Engl J Med. 2016 Aug 11;375(6):556-65. doi: 10.1056/NEJMra1507638. N Engl J Med. 2016. PMID: 27509103 Review. No abstract available.
Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Tashkin DP, et al. Among authors: wigley f. N Engl J Med. 2006 Jun 22;354(25):2655-66. doi: 10.1056/NEJMoa055120. N Engl J Med. 2006. PMID: 16790698 Free article. Clinical Trial.
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM. Chung L, et al. Arthritis Rheum. 2009 Mar;60(3):870-7. doi: 10.1002/art.24351. Arthritis Rheum. 2009. PMID: 19248104 Free article. Clinical Trial.
A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis.
Herrick AL, Murray AK, Ruck A, Rouru J, Moore TL, Whiteside J, Hakulinen P, Wigley F, Snapir A. Herrick AL, et al. Among authors: wigley f. Rheumatology (Oxford). 2014 May;53(5):948-52. doi: 10.1093/rheumatology/ket421. Epub 2014 Jan 31. Rheumatology (Oxford). 2014. PMID: 24489014 Clinical Trial.
The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD. Bello RJ, et al. Arthritis Rheumatol. 2017 Aug;69(8):1661-1669. doi: 10.1002/art.40123. Epub 2017 Jun 26. Arthritis Rheumatol. 2017. PMID: 28426903 Free PMC article. Clinical Trial.
Treating Raynaud phenomenon: Beyond staying warm.
Shapiro SC, Wigley FM. Shapiro SC, et al. Cleve Clin J Med. 2017 Oct;84(10):797-804. doi: 10.3949/ccjm.84a.17025. Cleve Clin J Med. 2017. PMID: 28985172 Free article. Review.
335 results